Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Inclusion Criteria

• •Diagnosis of advanced or metastatic NSCLC. Group A must be ALK negative NSCLC and Group B must be ALK positive NSCLC
• •Group A at least one prior regimen of therapy
• •Group B any number of prior regimens.
• •Mandatory tumor tissue available
• •At least one measurable lesion
• •ECOG Performance status 0 or 1
• •Adequate bone marrow, renal, liver and pancreatic function
• •Negative pregnancy test for females of childbearing potential
• •Group B Phase 2: No prior systemic treatment for advanced or metastatic disease (adjuvant and/or neoadjuvant therapies are allowed if completed at least 6 months prior to study entry. No prior tyrosine kinase inhibitor therapy is allowed at any time prior to study entry)